| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.1 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.052 | 0.1 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.054 | 0.1 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.045 | 0.1 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | UNC1215 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | -0.047 | 0.1 |
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.1 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.057 | 0.1 |